Belgian drugmaker UCB, BoneBot’s developer, said licensing it out to ImageBiopsy could see it brought into clinical practice by 2023, according to the report.
The AI focuses on identifying small vertebral compression fractures and distinguishing them from other problems such as vertebral degeneration. It will be integrated into ImageBiopsy’s existing AI-based platform, according to pharmaphorum.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.